Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sativex PK under varying oral pH
NCT02240160Phase 1Terminated
- Sponsor
- GW Pharmaceuticals
- Start
- Aug 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of cannabidiol in multiple sclerosis (MS) (3 arms), sponsored by GW Pharmaceuticals. Primary endpoints: Pharmacokinetic parameters of THC and Pharmacokinetic parameters of CBD. Started Aug 2014; status: terminated.
02
Drugs
cannabidiol
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02240160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02240160.